Measure happens after the US government pressure period on the high drug costs in the country; To make a discount, company established partnerships, as with Pharmacy Novocare
New pharmacist Nordisk announced a 50% cut in the price of the drug us. The measure is intended for patients who pay for cash treatment without health insurance coverage. The decision occurs after a period of intense US government pressure on the high drug costs in the country. With the reduction, the value of Ozempic, which has the week as an active ingredient, may be $ 499 per month, equivalent to $ 2,700.
To make the discount viable, the company has established partnerships, such as Pharmacy Novocare and the Goodrx platform. Through Goodrx, the drug WeGovy, also from Novo Nordisk and used to treat obesity, will be offered for the same value.
Price reduction is seen as a direct response to criticism of the cost of treatments, a agenda that has been raised by politicians, including the president. In addition, the measure aims to combat the market of manipulated and unapproved versions of the drug, which have become popular during periods of supply scarcity and are considered potentially insecure.
The news had an immediate impact on the financial market:
- The actions of Novo Nordisk rose up to 7.8%;
- The actions of GoodRx They fired 39%, registering their highest discharge since September 2020;
The direct sales strategy and partnerships to facilitate access follows a movement similar to that of its competitor, Eli Lilly, in an increasingly competitive market attentive to the demand for more affordable treatments.
*With information from Bruno Meyer
*Report produced with the aid of AI
